36 results about "Glimepiridum" patented technology

The invention discloses a Glimepiride tablet, wherein the Glimepiride tablet comprises the following components: Glimepiride tablet bulk pharmaceutical chemical, lactose, sodium starch glycolate, microcrystalline cellulose, microcrystalline silica gel and magnesium stearate at the weight ratio of (2-6):(60-90):(10-30):(10-60):(2-6):1, wherein the Glimepiride tablet bulk pharmaceutical chemical ispowder with the particle size less than 2 mu m. The invention also discloses a preparation method. With regard to Glimepiride, pharmaceuticals are smashed into particulates with the particle size less than 2mu m by an improved technology, and the hydrophilicity of the pharmaceuticals is improved; and the problem that the dissolution velocity of the pharmaceuticals is influenced is solved. Statistical analysis indicates that the average dissolution degree is above 98.5% by adopting the improved prescription and technology, and the accelerated test result for 6 months is very stable; and the research on primary pharmacokinetic parameters indicate that the preparation has the advantages of better dynamic course in human bodies and better absorption elimination properties through the checkingof statistics.

The invention provides glimepiride orally disintegrating tablets. The orally disintegrating tablets are prepared by an inclusion technology, effectively solve the problems about the taste and disintegration of a main medicine, are convenient to operate, transport and store, have broad application range, and are suitable for large-scale production.

The invention discloses a glimepiride dispersible tablet. After filling agent lactose contained in the prescription is screened by a 150-mesh sieve, micronization treatment does not need to be carried out to the basic remedy, glimepiride, the dissolution rate at the time of 15 minutes can reach above 90 percent, all indexes meet the medical standard, and the stability is good. The invention also discloses a preparation method of the dispersible tablet, which has no special requirement on equipment, and is simple in operation and suitable for industrial production and application.

The invention relates to the field of pharmaceutical preparations, and in particular discloses a compound controlled-release preparation of metformin hydrochloride and glimepiride and a preparation method of the controlled-release preparation. The controlled-release preparation disclosed by the invention consists of an internal controlled-release tablet which contains the metformin hydrochloride and an external drug-loaded coating which contains the glimepiride, wherein the internal controlled-release tablet which contains the metformin hydrochloride comprises a tablet core, an insoluble semipermeable coating film and drug-release small pores. The controlled-release preparation disclosed by the invention can significantly improve the linearity and the uniformity of drug release, the process (the preparation method) is simple and easy to implement, and the tablet is better in compressibility; and the glimepiride, without micronizing treatment or other special treatment, is excellent in dissolving effect.

The invention relates to a glimepiride tablet and a preparation method thereof. The tablet is prepared by the following method: dissolving glimepiride in a sodium hydroxide solution, adding mesoporous silicon dioxide, stirring evenly, and stirring Add glacial acetic acid to this solution, the glimepiride and mesoporous silica complex precipitates, filter, dry, then mix with fillers and disintegrants, granulate, dry, add lubricant to the dry granules, Formed into tablets. Compared with the prior art, the tablet prepared by the invention dissolves rapidly in water, has a simple preparation process and is suitable for industrial production.

The invention provides a specific primer for detecting the T1369G polymorphic site (rs757110) genotype of the SUR1 gene by a PCR method, and the specific primer is used in the preparation of reagents for detecting the T1369G polymorphic site of the SUR1 gene by PCR amplification of biological samples The application in the invention, the SUR1 gene T1369G polymorphic site detection kit containing specific primers and the application of the detection kit to predict the effect of sulfonylurea drugs. Sulfonylurea drugs are selected from glibenclamide, glibenclamide, glibenclamide, glibenclamide, glimepiride, glibenclamide, glibenclamide, glibenclamide, glibenclamide , glipizide, gliclazide, glipizide, and gliquidone, preferably gliclazide or glimepiride.

The invention relates to a preparation method of glimepiride intermediate compound I, which belongs to the technical field of preparation of raw materials. The preparation method of the present invention comprises the following steps: reacting compound II and diphenyl carbonate under the catalysis of a base (refer to Synlett, 28(18), 2495-2498; 2017) to prepare compound IX; then compound IX and 4‑(2‑Aminoethyl)benzenesulfonamide is fed at a ratio of 1:1, a weak acid is added, isopropanol is added, and the reaction is heated under reflux. The technical scheme of the present invention provides a method for preparing a high-purity glimepiride intermediate.

The invention relates to a preparation method of glimepiride crystal form I, which belongs to the technical field of preparation of raw materials. The preparation method of the Limepiride crystal form I of the present invention comprises the following steps: dissolving the crude glimepiride in an aqueous alcohol solution, adding an appropriate amount of ammonia water, stirring to dissolve; filtering, adding acetic acid to the filtrate, and neutralizing the filtrate Ammonia in the crystalline form II, to obtain glimepiride crystal form II; to the crystal form II, add a ketone solvent 4 to 8 times its mass, stir at a temperature range of 10 to 35 °C for more than 10 hours, filter, and bake at 70 °C dry to obtain the glimepiride crystal form I product. The invention obtains a high-quality glimepiride crystal form I bulk drug.

The invention discloses a qualitative analysis detection method for illegally mixed high-polar chemical anti-diabetic components in anti-diabetic traditional Chinese medicine products. The method comprises the following steps that: 1) high efficient liquid phase chromatography conditions: an ammonium acetate-triethylamine-acetonitrile moving phase system and a C18 chromatographic column with certain specification are used, the wavelength is detected by ultraviolet, and the flow rate is 1.0ml / min; 2) analysis result: glibenclamide, glipizide, gliclazide, glimepiride, gliquidone, repaglinide, nateglinide, rosiglitazone and pioglitazone hydrochloride can realize the complete separation; 3) result judgment: when retention time of a chromatographic peak in an anti-diabetic traditional Chinese medicine product is consistent with that of anti-diabetic medicine in the step 2) and the apparent absorption is shown out, which indicate that the anti-diabetic medicine is contained in the sample tobe tested. The method has the advantages of quickness, simplicity, convenience, high sensitivity, strong specialization, broad coverage and so on.

The invention belongs to the technical field of medicinal chemistry and particularly relates to a preparation method of a glimepiride impurity. The preparation method comprises the following steps: dropwise adding acetic anhydride into a solution of 2-phenethylamine and an organic solvent with a low boiling point to be subjected to reaction to generate N-acetyl phenethylamine; dropwise adding chlorosulfonic acid into the N-acetyl phenethylamine at the temperature of lower than 20 DEG C to be subjected to chlorosulfonation reaction, and performing hydrolysis after the reaction is completed to remove excess chlorosulfonic acid; performing filtration and washing to obtain an impurity J benzenesulfonyl chloride; performing ammonolysis on the impurity J benzenesulfonyl chloride to obtain an impurity J benzene sulfonamide; in acetone, enabling the impurity J benzene sulfonamide to firstly react with a catalyst and then react with trans-p-methylcyclohexyl isocyanate to obtain an impurity J acetyl substance; enabling the impurity J acetyl substance and ethanol to be subjected to alcoholysis under the condition of the catalyst to generate an impurity J and ethyl acetate; and performing refining to obtain a high-purity impurity J. The purity of the glimepiride impurity J prepared by the method is high, the liquid phase content of the glimepiride impurity J is greater than 98.5%, the rawmaterials used in the method are easily available, the process parameters are controllable, and the reaction is mild.